Crypto valuation is changing. Capital is no longer focused only on traditional metrics such as TVL, active addresses, or fee revenue. The assets being repriced are increasingly those with strong narratives, shrinking circulating supply, institutional backing, and credible room for user growth. TON and BIO stand out as two of the clearest examples of this shift.
They come from very different corners of the market. TON is tied to the idea of a Web2 super-app becoming a Web3 gateway, while BIO is linked to Crypto’s attempt to reshape financing for science and intellectual property. Yet the market is reading them through a similar lens: money is flowing not simply toward what already has the strongest fundamentals, but toward assets that can support a much larger long-term story.
TON’s rerating is tied to Telegram’s distribution power
TON is not a new story. It began as a Telegram-backed blockchain project led by Pavel Durov, before Telegram was forced out under pressure from the US SEC. For a time, the market treated TON as a dead-end project. Over the past year, that view changed sharply, and TON returned as one of the strongest Layer1 assets in the market.
The driver is more than a generic “Telegram trade.” What the market is now seriously pricing in is a simple question: what happens if Telegram’s billion-scale user base actually starts entering Crypto? That is the central source of upside in the TON narrative. Unlike many chains that still depend mainly on internal rotation among crypto-native users, TON’s core value is not just technical throughput. It comes from Telegram’s built-in traffic, global reach, frequent social interaction, payment potential, and strong network effects inside communities.
An equally important part of the story is usability. Most Web3 products still ask users to download wallets, store seed phrases, and learn how gas and addresses work. TON’s pitch is different. Users may not even need to realize they are interacting with blockchain infrastructure at all. That is why the breakout of projects such as Notcoin, DOGS, and Hamster Kombat has been interpreted less as proof of product quality and more as evidence of Telegram’s ability to distribute Web3 activity through familiar social behavior.
TON’s biggest strength is also its main risk
Recent developments have reinforced this market view. The source points to several signals: Telegram becoming TON’s largest validator, Pavel Durov publicly backing TON again, lower TON network fees, and deeper wallet and payment integration through Telegram Mini Apps. Together, these moves suggest that Telegram is not merely supportive of TON. It is actively pushing TON toward a role inside its own economic infrastructure.
That same dependence creates risk. TON’s valuation rests heavily on assumptions that Telegram will keep embracing Crypto, that it will continue supporting on-chain economic activity, and that Durov will remain committed to privacy and decentralization. The source also notes the pressure surrounding Durov, including European demands on content moderation, the regulatory episode in France, disputes around anonymous social platforms and privacy, and broader sensitivity from governments toward crypto payments.
So TON’s risk profile is not the same as that of a typical standalone chain. Its upside comes from ecosystem dependence, and that dependence also concentrates the downside.
BIO is a bet on changing how science gets funded
BIO follows a completely different path. If TON is about user acquisition, BIO is about capital formation in research. It belongs to DeSci, or decentralized science, a sector that has drawn growing attention over the past year. After years of trying to reshape finance, gaming, social products, art, and payments, Crypto is now pushing into a larger and more difficult area: research and intellectual property, especially in sectors such as biotech, longevity, AI-driven drug discovery, and genetic engineering.
BIO’s target problem is straightforward. Traditional scientific funding is slow and often inefficient, especially for early-stage research with long development cycles and high uncertainty. Those timelines can stretch for years, sometimes more than a decade, which makes them hard for traditional venture capital to absorb. Crypto markets, by contrast, have often been willing to fund high-risk projects with large long-term optionality.
What sets BIO apart is that it is not framed only as a research DAO. It is presented more as a launchpad for scientific assets. The source identifies BioXP and Ignition Sale as key parts of the design. The model is built around users holding and staking BIO to gain access to future research funding opportunities, participate early in new scientific asset issuance, and help form an on-chain capital market for research. In that sense, BIO looks less like standard DeFi and more like a platform for scientific IPO-style access.
BIO still trades mostly on long-range expectations
The market case for BIO is not based on proven revenue generation today. It is tied to several broad narratives: the AI-biotech wave, the longevity economy, decentralized science, and the tokenization of research assets. The source also says that public support for DeSci from Arthur Hayes and Binance Labs helped push investors to treat the sector as a possible capital theme for the AI era.
Still, the weaknesses are clear. TON at least has a real user distribution channel. BIO, by comparison, still derives much of its value from narrative rather than realized adoption. Scientific research is difficult to evaluate, and the hardest question remains unresolved: how should research output be priced? Determining whether a scientific project has value can require years of validation, clinical testing, academic agreement, and commercial execution. Traditional venture capital firms already struggle with that process. The source makes no claim that on-chain community governance has solved it.
That leaves BIO as a high-risk, high-volatility, high-narrative-density asset. Buying it today is closer to a wager on whether Crypto can reshape research financing over the next five to ten years.
The market is paying for future industrial change
Looking at TON and BIO together helps explain the current market style. In earlier cycles, many projects won valuation through TVL, on-chain revenue, and user metrics. Now more capital is paying attention to distribution gateways, capital narratives, structural social change, and the possibility of long-term industry reorganization. TON represents the fusion of Web2 platforms with Crypto. BIO represents the financialization of high-value real-world sectors through Crypto.
That is why some older valuation frameworks are losing traction. The market is no longer pricing only what a project is today. It is pricing expected user scale, expected industry restructuring, and expected capital flows over the years ahead. The assets drawing the strongest attention are not simply “altcoins” in general, but those that can convince the market they may alter the structure of a major industry.